Research analysts at TD Cowen started coverage on shares of Astria Therapeutics (NASDAQ:ATXS – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $35.00 price target on the biotechnology company’s stock. TD Cowen’s price target points to a potential upside of 206.21% from the company’s current price.
Several other equities analysts have also commented on ATXS. Oppenheimer reduced their target price on shares of Astria Therapeutics from $29.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Friday, May 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Friday, May 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.00.
Check Out Our Latest Report on ATXS
Astria Therapeutics Price Performance
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). As a group, equities research analysts expect that Astria Therapeutics will post -1.56 EPS for the current year.
Institutional Investors Weigh In On Astria Therapeutics
Several institutional investors have recently added to or reduced their stakes in ATXS. RA Capital Management L.P. purchased a new stake in Astria Therapeutics during the 1st quarter valued at $62,115,000. Perceptive Advisors LLC boosted its position in Astria Therapeutics by 82.9% during the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after buying an additional 1,814,608 shares during the period. Armistice Capital LLC purchased a new stake in Astria Therapeutics during the 4th quarter valued at $12,119,000. Artal Group S.A. purchased a new stake in Astria Therapeutics during the 1st quarter valued at $12,445,000. Finally, Vivo Capital LLC boosted its position in Astria Therapeutics by 47.7% during the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock valued at $19,067,000 after buying an additional 801,528 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.
About Astria Therapeutics
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Featured Articles
- Five stocks we like better than Astria Therapeutics
- How to Use the MarketBeat Dividend Calculator
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What is a Death Cross in Stocks?
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Earnings Per Share Calculator: How to Calculate EPS
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.